Doses studied
Epitalon Dosage in the Research Literature
What was administered, to which species, by which route — reported as study data, never as a protocol for a person.
The short version
This page describes the Epitalon doses that appear in published studies — and only that. It is not a guide to taking the peptide, and there are no human dose recommendations anywhere on this site, because none exist in approved medicine: Epitalon is investigational and unapproved. In animal experiments the amounts were tiny, given by injection under the skin on intermittent monthly schedules; in lab-dish experiments the peptide was simply added to the culture at microgram-per-milliliter concentrations. The human work used parenteral (injected) courses over a few weeks at a time, on schedules that were never standardized to Western trial-reporting rules. One question that comes up constantly — how long the peptide lasts in the body, its half-life — has no published human answer at all. Everything below is reported in the third person, attached to a species and a route, exactly as the studies framed it.
Epitalon dosage as studied in animals and cells
The most-cited animal schedule, from the SHR-mouse lifespan study, was 1.0 μg per mouse — roughly 30-40 μg/kg — given subcutaneously for five consecutive days each month, beginning at three months of age [3]. Lower-dose rodent carcinogenesis work used 0.1 μg per mouse [12], and a rat colon-carcinogenesis model used a single 1 μg subcutaneous dose [16]. In cell studies, the 2025 human-cell-line work added Epitalon at 0.1, 0.2, 0.5, and 1 μg/mL — four days for cancer cells, three weeks at 1 μg/mL for normal cells [5]. The Drosophila lifespan study worked at extraordinarily low medium concentrations, on the order of 10⁻⁶ weight-percent [7]. The pattern across the literature is consistent: very small amounts, intermittent dosing, and a strong reliance on the subcutaneous route in whole-animal work.
Routes that have been studied
Subcutaneous injection is the predominant route in both the rodent and the reported human work [3]. In vitro studies simply add the peptide to the culture medium [1]. A separate line of rat work used the intranasal route to study neocortical neuron activity, and the Russian clinical and observational studies used parenteral courses [2]. There is no oral Epitalon efficacy study in the cited literature — unsurprising for a small linear peptide, which the digestive tract would be expected to break down. Route matters for interpretation: a result obtained by adding peptide directly to cells in a dish says nothing about whether the same exposure is achievable in a living body by any route.
Epitalon half life: what is known and what is inferred
The Epitalon half life is one of the most-asked and least-answered questions about the peptide. No formal pharmacokinetic half-life study has been published for Epitalon in humans [4]. As an unmodified linear tetrapeptide with no protective modifications, it would be expected to undergo rapid proteolytic degradation in plasma, consistent with the very short half-lives — generally measured in minutes — that small peptides show. But that figure is an inference from peptide chemistry, not a measured Epitalon value, and the often-repeated "minutes" number online should be read that way. The practical consequence researchers draw from this short presumed half-life is the use of intermittent, repeated dosing rather than continuous exposure — which is also why community protocols are described as cycles rather than daily long-term use.
Epitalon side effects in the context of dose
Because no human dose is established, no dose-related Epitalon side effects are characterized either. In the small published animal and human studies, reported adverse events were few, but that reflects study size and design rather than a controlled safety profile [4]. The community-reported complaints — injection-site soreness or bruising, occasional drowsiness, mild headache — are not tied to any specific amount and read as generic features of subcutaneous self-injection or non-specific effects, not established dose-dependent toxicities. The cited cautions that do matter — the theoretical telomerase-and-cancer concern [5] and the unverified purity of research-grade material — are independent of dose. The full safety reading is on the effects page.
Handling and stability in research practice
Handling conventions described in research practice are just that — conventions, not directions for use. Lyophilized (freeze-dried) peptide is typically stored at -20 °C. Once reconstituted, solution is generally refrigerated at 2-8 °C and used within a few weeks, since repeated freeze-thaw cycling degrades short peptides. These are general laboratory handling norms, not manufacturer or clinical instructions, and they say nothing about whether any preparation is safe or appropriate for human use. As with everything on this page, the framing is research context only: what studies did with the material, not what a person should do with it.